The U.S. government is committing millions of dollars in support for leading Ebola vaccine programs at Merck and Johnson & Johnson.
Bavarian Nordic has secured a U.S. smallpox vaccine stockpiling contract potentially worth $539 million.
In a temporary break from its corporate drama, Sinovac posted positive topline data from a phase 3 study of its chickenpox vaccine.
Here's some other vaccine news of note for this week.
Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.
Dynavax is assuming the daunting task of challenging a Big Pharma with a small internal team.
After a major cancer vaccine misstep, Bavarian Nordic reported positive six-week data from an ongoing phase 2 study on its RSV vaccine candidate.
Inovio and GeneOne have started a clinical study of their MERS vaccine in South Korea, where the virus took 36 lives in a 2015 outbreak.
Johnson & Johnson and a U.S. development agency are zeroing in on pandemic flu in a novel deal focusing on vaccine and flu drug candidates.